Skip to main content
ACTU logo

ACTU · Actuate Therapeutics, Inc.

Track ACTU — free
$1.27 +0.04 (+3.25%) At close · Aug 21
Market Cap
$30.50M
Shares
24.01M

Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.

Net Income
-$22.23M +18.5%
FY2025 Net Income FY2023–FY2025
Diluted EPS
-$1.06 +67.5%
FY2025 Diluted EPS FY2023–FY2025
Operating Cash Flow
-$19.21M +12.1%
FY2025 Operating Cash Flow FY2023–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Line Item TTM FY2025 FY2024 FY2023
$8.94M $10.29M $18.68M $21.71M
$11.83M $12.2M $6.48M $3.27M
$20.77M $22.5M $25.16M $24.97M
-$20.77M -$22.5M -$25.16M -$24.97M
$20.25K $20.25K $18.72K $43.64K
$339.84K $287.71K $222.29K $352.67K
$319.59K $267.46K -$2.12M $229.21K
$800 $800 $0
-$20.45M -$22.23M -$27.29M -$24.74M
USD/shares -$1.06 -$3.26 -$17.24
USD/shares -$1.06 -$3.26 -$17.24
shares 21.02M 8.37M 1.43M
shares 21.02M 8.37M 1.43M
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue
Peer median 2.88×
EV/EBIT
P/E (TTM)
Peer median 5.92×

Peer medians compare against the 268 similar-size Biotechnology companies (of 546 listed).

Key facts CIK 1652935 CUSIP 005083100 13F (30d) 52 filings 52 filers Visit website Investor relations